Table 1.
Efficacy in evaluable patients
| Eltanexor (10 mg) N = 5 |
Eltanexor (20 mg) N = 10 |
Total N = 15 |
|
|---|---|---|---|
| ORR, n (%) | 3 (60) | 5 (50) | 8 (53.3) |
| MCR, n (%) | 3 (60) | 4 (40) | 7 (46.7) |
| HI, n (%) | 1 (20) | 2 (20) | 3 (20) |
| HI with MCR | 1 (20) | 1 (10) | 2 (13.3) |
| HI with SD | 0 | 1 (10) | 1 (6.7) |
| SD, n (%) | 2 (40) | 2 (20) | 4 (26.7) |
| PD, n (%) | 0 | 3 (30) | 3 (20) |
| Treatment duration, weeks | 15 | 12 | 13 |
| Median time to response, weeks | 8.1 | 9.1 | 8.4 |
| Median duration of response, weeks (95% CI) |
7.86 (NE, NE) |
25.29 (13.12, NE) |
19.21 |
ORR overall response rate; MCR marrow complete remission; HI hematologic improvement; SD stable disease; PD progressive disease; CI confidence interval; NE not evaluable